Spanish law firm Araoz & Rueda, led by partner Pedro Rueda and associates Guillermo Bueno and Casilda Redondo, has advised British private equity fund Charme Capital Partners on the sale of its majority stake in the Valencia-based company Igenomix, leading provider of genetic testing services for reproductive health patients and clinics, to the EQT investment group. Araoz & Rueda also advised Charme Capital on the acquisition of Igenomix in 2016.
Charme Capital has been also advised by Arcano on the financial side, while Allen & Overy and PwC have advised EQT on the legal and financial aspects, respectively.
Initially created in 2011 as a spin-off from Instituto Valenciano de Infertilidad (IVI), Igenomix is today a fully independent organization, and offers pioneering genetic testing services in reproductive medicine. Headquartered in Valencia, the company has laboratories in Miami, New York, Los Angeles, Mexico, Sao Paulo, New Delhi and Dubai, and works closely with IVF clinics worldwide.
Charme Capital Partners, a mid-market private equity firm with offices in Milan, London and Madrid, takes a Pan-European approach investing in companies with strong growth and internationalisation prospects. Since its founding in 2003 by Luca and Matteo di Montezemolo, the Charme funds have raised around EUR1 billion.
EQT is a leading investment firm with approximately EUR 61 billion in raised capital across 29 funds around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees.
With this acquisition, EQT will support Igenomix’s continued international growth journey by leveraging EQT’s strong healthcare expertise, global platform and network of Industrial Advisors. Charme will continue to back the company in select R&D initiatives.
Araoz & Rueda
